Q.Suite positioned as improvement in cancer treatment assessment.
GE Healthcare today officially introduced Q.Suite, tools designed to improve PET for oncology treatment assessment by creating more consistent readings.
Thanks to its ability to indicate metabolic change, PET can reveal whether a given oncology treatment is working or not, even before a physical change in tumor size can show up in CT or MR images, according to Vivek Bhatt, general manager for PET at GE Healthcare.
But Standardized Uptake Value (SUV) readings have to be consistent for physicians to rely on data showing a change from the baseline. Variation control is needed.
Q.Suite offers stability through:
• Q.Freeze - Designed to be combine the quantitative benefits of 4D phase-matched PET/CT imaging into a single static image, eliminating motion, Q.Freeze is 510(k) pending at the FDA and is not available for sale in the United States.
• Q.Static - Adds basic motion correction techniques, reducing organ motion effects. The tool is meant to automatically isolate data when organs are in a low-motion state. The result is a single image series with reduced blurring from organ motion.
• Q.AC - An algorithm is designed to reduce potential variance in attenuation correction measurements, helping ensure that the attenuation coefficients used in image reconstruction are accurate.
• Q.Check - Establishes a link between the console and workstation to ensure that patient and exam data required for quantitative imaging is saved in the patient file before the exam is finished.
• Q.Core - Manages both PET acquisition and reconstruction processing at faster speeds.
• PET VCAR - Provides access to quantitative information, managing multiple lesions and multiple patient exams over time. PET VCAR now supports PERCIST.
GE also announced its new Discover PET/CT 710, capable of 128-slice imaging, and stressed its research on developing a fully integrated PET/MR.
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.